About 19 results found for searched term "AC220" (0.181 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1641 | Quizartinib (AC220) | FLT3 |
| AC220 | ||
| Quizartinib (AC220) is a uniquely potent and selective FLT3 inhibitor. | ||
| M8523 | ACT-462206 | Others |
| ACT-462206 is a orally active, brain penetrant, potent and selective dual orexin1/2 receptor antagonist (DORA). | ||
| M40752 | Quizartinib hydrochloride | FLT3 |
| AC220 hydrochloride | ||
| Quizartinib hydrochloride is a FLT3 inhibitor with IC50 values of 1.1 nM for Flt3-ITD and 4.2 nM for Flt3-WT, and is 10-fold more selective for Flt3 than for KIT, PDGFRA, PDGFRB, RET, and CSF-1R. It can be used in studies related to acute myeloid leukemia (AML). | ||
| M2014 | MC1568 | HDAC |
| MC1568 is a selective class II (IIa) histone deacetylas (HDAC II) inhibitor with IC50 of 220 nM. | ||
| M3420 | Diclofenac Sodium | COX |
| GP 45840 | ||
| Diclofenac Sodium is a non-selective COX inhibitor with IC50 of 60 and 220 nM for ovine COX-1 and -2, respectively. | ||
| M4642 | Albaspidin-AA | Antibiotic |
| The antibacterial activity of Albaspidin AA was 220 μM for Paenibacillus (P. SPAR). | ||
| M5572 | Diclofenac | COX |
| Diclofenac (diclofenac) is a COX inhibitor and has an IC50 of 60 and 220 nM for sheep COX-1 and -2, respectively. | ||
| M10633 | AS601245 | JNK |
| AS-601245 | ||
| AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 values of 150, 220, and 70 nM for JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. | ||
| M10866 | NSC-70220 | Others |
| NSC-70220 is a selective allosteric SOS1 inhibitor. NSC-70220 inhibits allosteric site activation and partially inhibits catalytic site activation. NSC-70220 has anti-cancer effects. | ||
| M11441 | CFT7455 | Ligand for E3 Ligase |
| CFT7455 is an orally active inhibitor of zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). CFT7455 is an anticancer agent that binds cereblon E3 ligase with high affinity (Kd 0.9 nM) (WO2022032132A1; Compound 1). | ||
| M21647 | MB710 | Mdm2 |
| MB-710 | ||
| MB710 is a stabilizer of oncogenic p53 mutation Y220C. MB710 binds tightly to the Y220C pocket and stabilizes p53-Y220C, with a Kd of 4.1 μM. MB710 shows anticancer activity in p53-Y220C cell lines. | ||
| M27719 | PhiKan 083 hydrochloride | p53 |
| PhiKan-083 hydrochloride ; PK083 hydrochloride | ||
| PhiKan 083 hydrochloride is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM[1], and a relative binding affinity (Kd) of 150 μM in Ln229 cells. | ||
| M28145 | FR122047 | COX |
| FR122047 (hydrochloride) is a selective and oral active inhibitor of COX-1 with an IC50 of 28 nM. FR122047 hydrochloride has antiplatelet, analgesic and anti-inflammatory effects in vivo. | ||
| M28262 | LP-922056 | Wnt/beta-catenin |
| LP-922056 is an orally active, highly potent Notum Pectinacetylesterase inhibitor with EC50s of 21 nM, 55 nM in human and mouse cellular assay, respectively. LP-922056 significantly increases midshaft femur cortical bone thickness in mice and rats. | ||
| M39054 | hCAI/II-IN-6 | Carbonic Anhydrase |
| hCAI/II-IN-6 is an orally active human carbonic anhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. | ||
| M42122 | JNK3 inhibitor-8 | JNK |
| JNK3 inhibitor-8 is a potent, delective, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 21, 2203, >10000 nM for JNK3, JNK2, JNK1, respectively. | ||
| M42653 | AChE/BChE-IN-15 | AChR/AChE |
| AChE/BChE-IN-15 is an AChE/BChE inhibitor, with IC50s of 20 nM and 220 nM respectively. | ||
| M42743 | ALPK1-IN-3 | NF-κB |
| ALPK1-IN-3 is an inhibitor of ALPK1 extracted from patent WO2022063153A1 compound T007. | ||
| M43013 | Rezatapopt | p53 |
| PC14586 | ||
| Rezatapopt is a first-in-class p53 reactivator that selectively binds to the mutated p53 Y220C protein and restores wild-type activity, used to inhibit solid tumor with p53 mutation. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
